Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France

Applied Health Economics and Health Policy

Volumn 6, Issue 4, 2008, Pages 199-216

  Standaert, Baudouin ^a   Parez, Nathalie ^b   Tehard, Bertrand ^c   Colin, Xavier ^d   Detournay, Bruno ^d  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b HÔPITAL LOUIS MOURIER   (France)

^c GLAXOSMITHKLINE   (France)

^d CEMKA EVAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; CHILD; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG COST; EMERGENCY WARD; FRANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PRACTITIONER; HEALTH STATUS; HEALTH VISITOR; HOSPITALIZATION COST; HUMAN; INFANT; MEDICAL FEE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; ROTAVIRUS; SEASONAL VARIATION; TREATMENT OUTCOME; VACCINATION; VIRAL GASTROENTERITIS; VIRUS INFECTION;

AGE DISTRIBUTION; ANALYSIS OF VARIANCE; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; DRUG COSTS; FRANCE; GASTROENTERITIS; HEALTH SERVICES RESEARCH; HUMANS; INFANT; MARKOV CHAINS; MODELS, ECONOMETRIC; OUTCOME ASSESSMENT (HEALTH CARE); REGRESSION ANALYSIS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEASONS; SENSITIVITY AND SPECIFICITY; VACCINATION; VACCINES, ATTENUATED;

EID: 65349102876     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.1007/bf03256134     Document Type: Article

References (43)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 May; 9 (5): 565-72
2. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006 Jan; 25 (Suppl. 1): S7-11
3. Brandt CD, Kim HW, Rodriguez WJ, et al. Pediatric viral gastroenteritis during eight years ofstudy. J Clin Microbiol 1983 Jul; 18(1): 71-8
4. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996 Oct 3; 335 (14): 1022-8
5. Melliez H, Boelle PY, Baron S, et al. Morbidity and cost of rotavirus infections in France [in French]. Med Mal Infect 2005; 35 (10): 492-9
6. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23 (10): 937-43
7. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370 (9601): 1757-63
8. Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness ofchildhood vaccination against rotavirus in France. Vaccine 2008 Jan 30; 26 (5): 706-15
9. Official medical tariff list (UCANSS) [online]. Available from URL: http://www.ucanss.fr/ [Accessed 2008 Nov 30]
10. Echelle des Couts (ENC). 2008 [online]. Available from URL: http://www.atih.sante.fr/?id = 000370000FFF [Accessed 2008 Nov 30]
11. College des Economistes de la Sante. French guidelines for the economic evaluation of health care technologies [online]. Available from URL: http://www.ces-asso org/docs/ France-Guidelines-HE-Evaluation.PDF [Accessed 2008 Nov 30]
12. Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ 2008; 11 (3): 471-84
13. Infectious Intestinal Disease Study Executive Committee. A report of the study of infectious intestinal disease in England. London: Food Standards Agency, 2000
14. Bresee JS, Glass RI, Ivanoff B, et al. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999 May 4; 17 (18): 2207-22
15. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004; 33 (8): 536-43
16. Fourquet F, Desenclos JC, Maurage C, et al. Acute gastroenteritis in children in France: estimates of disease burden through national hospital discharge data. Arch Pediatr 2003; 10(10): 861-8
17. Martinot A, Dumonceaux A, Grandbastien B, et al. Evaluation of the ambulatory treatment of acute diarrhoea in infants [in French]. Arch Pediatr 1997; 4 (9): 832-8
18. French general practitioners' Sentinelles network [online]. Available from URL: http://websenti b3e jussieu fr/sentiweb/ [Accessed 2008 Nov 30]
19. Clemens J, Rao M, Ahmed F, et al. Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement? Pediatrics 1993 Nov; 92 (5): 680-5
20. Newburg DS, Peterson JA, Ruiz-Palacios GM, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet 1998 Apr 18; 351 (9110): 1160-4
21. Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital- acquired rotavirus disease. Pediatr Infect Dis J 2006 Jan; 25 (Suppl. 1): S12-21
22. Institut de Veille Sanitaire. The fight against HIV/AIDS and sexually transmitted infections in France. 10 years of surveillance, 1999-2005 [online]. Available from URL: http://www.invs.sante.fr/publications/2007/10ans-VIH/ executive-summary-aids-vih.pdf [Accessed 2008 Nov 30]
23. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23 (7): 639-49
24. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004 Jul; 7 (4): 397-401
25. Smith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care 2001; 17 (2): 236-43
26. Sheldon TA. Discounting in health care decision-making: time for a change? J Public Health Med 1992 Sep; 14 (3): 250-6
27. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992 Apr; 1 (1): 71-6
28. Torgerson DJ, Raftery J. Economic notes: discounting. BMJ 1999 Oct 2; 319 (7214): 914-5
29. News from the scientific literature: the cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. V&I News-ECDC Newsletter on Vaccines and Immunisation 2008 Feb 13; 39: 3 [online]. Available from URL: http://ecdc.europa.eu/documents/pdf/080213 XXXVIV.pdf [Accessed 2009 Apr 2]
30. Hjelt K. Nosocomial virus infections in pediatric departments: rotavirus and respiratory syncytial virus. Ugeskr Laeger 1991 Jul 22; 153 (30): 2102-4
31. Le Roux P, Marshall B, Toutain F, et al. Nosocomial viral infections in a pediatric service: example of rotaviral gastroenteritis and respiratory syncytial viral bronchiolitis. Arch Pediatr 2004 Aug; 11 (8): 908-15
32. Maille L, Beby-Defaux A, Bourgoin A, et al. Nosocomial infections due to rotavirus and respiratory syncytial virus in pediatric wards: a 2-year study. Ann Biol Clin (Paris) 2000 Sep; 58 (5): 601-6
33. National Institute for Statistics and Economic Studies [Institut Nationale de la Statistique et des Etudes Econo- miques]. Activité, emploi et chomage selon le type de ménage et le nombre d'enfants [online]. Available from URL: http://www.msee fr/fr/ffc/chifcle-fiche asp?ref-id= NATCCF03128&tab-id=490&souspop=2 [Accessed 2008 Nov 30]
34. Giaquinto C, Van Damme P, Huet F, et al. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007; 195 (Suppl. 1): S36-44
35. Huet F, Largeron N, Trichard M, et al. Burden ofpaediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine 2007 Aug 21; 25 (34): 6348-58
36. Giaquinto C, Van DP, Huet F, et al. Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007; 195 (Suppl. 1): S26-35
37. Huppertz HI, Forster J, Heininger U, et al. The Parental Appraisal of the Morbidity of Diarrhea in Infants and Toddlers (PAMODI) survey. Clin Pediatr (Phila) 2008; 47 (4): 363-71
38. Goossens LM, Standaert B, Hartwig N, et al. The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands. Vaccine 2008; 26: 1118-27
39. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales: part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25 (20): 3971-9
40. Standaert B, Marocco A, Assael B, et al. Analisi di costoefficacia della vaccinazione universale in Italia con il vac- cino Rix4414 contro i rotavirus. PharmacoEconomics Ita Res Articles 2008; 10 (1): 23-35
41. Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007 Apr; 119 (4): 684-97
42. Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 2008; 27 (1):S20-7
43. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 2006 Dec; 6 (12): 805-12